Ryoncil® (remestemcel-L-rknd) – New orphan drug approval
December 18, 2024 - The FDA announced the approval of Mesoblast’s Ryoncil (remestemcel-L-rknd), for the treatment of steroid refractory acute graft versus host disease (SR- aGvHD) in pediatric patients 2 months of age and older.
